ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings
  • Abstract Number: 2638 • ACR Convergence 2024

    Defining Sonographic Enthesitis in Psoriatic Arthritis: Developing a Data- and Expert-driven Diagnostic Criteria for Inflammatory Enthesitis at the Single Enthesis Level

    Andre Lucas Ribeiro1, Sibel Aydin2, Gurjit Kaeley3, Fahmeen Afgani4, Catherine Bakewell5, Marcos Rosemffet6, Minna Kohler7, Amir Haddad8, Maria S. Stoenoiu9, Ari Polachek10, josefina marin11, Arnon Katz12 and Lihi Eder13, 1Women's College Hospital & University of Toronto, Porto Alegre, Rio Grande do Sul, Brazil, 2University of Ottawa - Ottawa, Ottawa, ON, Canada, 3UF COM-J, Ponte Vedra Beach, FL, 4Women's College Hospital, Toronto, Canada, 5Intermountain Healthcare, Salt Lake City, UT, 6Instituto de Rehabilitación Psicofísica, Capital Federal, Argentina, 7Massachusetts General Hospital, Boston, MA, 8Carmel Medical Centre, Haifa, Israel, 9Cliniques Universitaires Saint-Luc, Brussels, Belgium, 10Tel-Aviv Medical Center, Tel-Aviv, Israel, Petah-Tikva, Israel, 11Hospital Italiano de Buenos Aires, buenos aires, Argentina, 12GRAPPA - Patient Research Partner, Haifa, Israel, 13University of Toronto, Women’s College Hospital and Department of Medicine, Toronto, ON, Canada

    Background/Purpose: Clinical enthesitis occurs in 30-40% of psoriatic arthritis (PsA) patients, but its clinical diagnosis is challenging due to similarities to non-specific entheseal pain. Despite…
  • Abstract Number: 2687 • ACR Convergence 2024

    Therapeutic Choices in Systemic Sclerosis Associated Interstitial Lung Disease, a Survey of International Experts

    Michael Macklin1, Iazsmin Bauer Ventura1 and Dinesh Khanna2, 1University of Chicago, Chicago, IL, 2University of Michigan, Ann Arbor, MI

    Background/Purpose: The therapeutic options for systemic sclerosis-associated interstitial lung disease (SSc-ILD) have evolved rapidly, with recent guidelines released by the ACR and American Thoracic Society…
  • Abstract Number: 2690 • ACR Convergence 2024

    ANCA IgG Promotion of Neutrophil Recruitment, Migration and Vascular Damage in ANCA Associated Vasculitis May Be Enhanced by Hypoxia

    Noelle Pisacano, Amrita Dhutia, Stephen Rothery, Charles Pusey, Edwin Chilvers, Andrew Cowburn, Katharine Lodge and Maria Prendecki, Imperial College London, London, United Kingdom

    Background/Purpose: Neutrophils are main mediators of disease in ANCA associated vasculitis (AAV). Pathogenic ANCA IgG on neutrophils promotes neutrophil adhesion and migration at the endothelium.…
  • Abstract Number: PP07 • ACR Convergence 2024

    My Journey with Diffuse Scleroderma and Interstitial Lung Disease: A Pharmacist’s Perspective

    Joseph Washington, Cencora, Washington, DC

    Background/Purpose: Since my diagnosis with diffuse scleroderma and ILD, I have balanced the roles of patient and young pharmacist. A duality that has surely impacted…
  • Abstract Number: 2626 • ACR Convergence 2024

    Identifying Homogeneous Endophenotypes in Childhood-Onset Systemic Lupus Erythematosus with Similarity Network Fusion

    Nicholas C Chan1, Nicholas Gold2, Deborah Levy2, Andrea Knight3, Earl Silverman4, Daniela Dominguez5, Lawrence Ng2, Lauren Erdman2 and Linda Hiraki2, 1University of Toronto, Toronto, ON, Canada, 2The Hospital for Sick Children, Toronto, ON, Canada, 3Division of Rheumatology, The Hospital for Sick Children; Neurosciences and Mental Health, SickKids Research Institute; Department of Paediatrics, University of Toronto, Toronto, ON, Canada, 4Silverman, Toronto, ON, Canada, 5The Hospital for Sick Children, Toronto, Canada

    Background/Purpose: Childhood-onset Systemic Lupus Erythematosus (cSLE) is a clinically heterogeneous autoimmune disease. We hypothesized that similarity network fusion (SNF) a data driven method would identify…
  • Abstract Number: PP06 • ACR Convergence 2024

    Sweat It Out: How the Sauna Has Helped Me Cope with Rheumatoid Arthritis

    Eileen Davidson, Global Healthy Living Foundation, Burnaby, BC, Canada

    Background/Purpose: Since receiving my rheumatoid arthritis (RA) diagnosis in 2015, I have found that one of my top five strategies to manage my symptoms is spending…
  • Abstract Number: 2636 • ACR Convergence 2024

    Multi-centre Validation of a Serum Protein Biomarker Signature (RAPsA Dx), Which Discriminates Psoriatic Arthritis (PsA) from Rheumatoid Arthritis (RA)

    Stephen Pennington1, Ruoyi Zhou2, Jonathan Brady2, Bruna Wundervald2, Andrew Parnell3, Ciarán Duffy2, Robert Perryman2, James Waddington4, Neil McHugh5, Deepak Jadon6, David Simon7, Filippo Fagni8, Georg Schett9, Fraser Morton10, Aurelie Najm10, Stefan Siebert11, Laura Coates12 and Oliver FitzGerald13, 1UCD, Dublin, Dublin, Ireland, 2Atturos, DUBLIN, Dublin, Ireland, 3NUIM, Maynooth, Ireland, 4Agilent, Manchester, United Kingdom, 5University of Bath, Bath, United Kingdom, 6Cambridge University, Cambridge, United Kingdom, 7Charité - Universittsmedizin Berlin, Berlin, Germany, 8Department of Internal Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander University (FAU) Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany, Deutsches Zentrum für Immuntherapie (DZI), Friedrich Alexander University Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany, Erlangen, Germany, 9Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany, 10University of Glasgow, Glasgow, United Kingdom, 11School of Infection and Immunity, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom, 12University of Oxford, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Oxford, United Kingdom, 13UCD, Dublin 6, Dublin, Ireland

    Background/Purpose: In a previous study, we reported the discovery and evaluation of a serum protein (22 peptide) signature (RAPsA Dx) which, when using random forest machine…
  • Abstract Number: PP10 • ACR Convergence 2024

    Walking Away from Arthritis Pain: Exercise Helped Me Manage Sarcoidosis and Osteoarthritis Physically and Emotionally

    Bridget Kelly, Hospital for Special Surgery, Rockville Centre, NY

    Background/Purpose: In 2004, we moved to a new home with 2 small children, when I started experiencing terrible joint pain. For 2 years I was…
  • Abstract Number: 2660 • ACR Convergence 2024

    Developing Predictive Models for the Diagnosis of VEXAS Syndrome

    Daniel Montes1, Andrew C. Hanson2, Hannah Langenfeld1, Cynthia Crowson1, Mrinal Patnaik1, Ronald Go1, Alexander Hines1, Kambiz Kalantari1, Yael Kusne3, Terra Lasho2, Abhishek Mangaonkar1, Horatiu Olteanu1, Kaaren Reichard1, Megan Sullivan4, David Viswanatha1, Kenneth Warrington1 and Matthew Koster1, 1Mayo Clinic, Rochester, MN, 2Mayo Clinic, Rochester, 3Mayo Clinic, Phoenix, AZ, 4Mayo Clinic Arizona, Scottsdale, AZ

    Background/Purpose: VEXAS (Vacuoles, E1 enzyme, X-linked, Autoinflammatory, Somatic) syndrome is a recently identified autoinflammatory disorder with a heterogenous presentation. Patients may experience delays in diagnosis…
  • Abstract Number: 2677 • ACR Convergence 2024

    N-Acetylcysteine Blocks the Mechanistic Target of Rapamycin in Pro-Inflammatory Effector-Memory CD4 and CD8 T Cells Re-Expressing CD45RA in Patients with Active Systemic Lupus Erythematosus

    Joy Park1, Lanlan Ji1, Jorge Cabezas1, Xiaojing Wang2, Bryan Blaker1, Dilip Rao1, Aparna Godavarthy1, Lucero Blaker1, FNU Ruchi1, Ioana Coman1, Nancy Olsen3, Joshua Lewis2, Mariko Ishimori4, Kyriakos Kirou5, Christina Donath1, Sara Kahlown6, Damira Sereda1, Marlene Marte Furment1, Sandy Nasr7, Sravani Lokineni1, rosalind Ramsey-Goldman8, Michael Weisman9, Arthur Weinstein10, Cynthia Aranow11, Banki Katalin12, Michael McDermott13, Daniel Wallace14 and Andras Perl1, 1SUNY, Syracuse, NY, 2SUNY Upstate Medical University, Syracuse, NY, 3Penn State University/Milton S Hershey, Hershey, PA, 4Cedars-Sinai Health System, Los Angeles, CA, 5Hospital for Special Surgery, New York, NY, 6SUNY Upstate University Hospital, Department of Medicine, Rheumatology Fellowship Program, Syracuse, NY, 7SUNY Upstate University Hospital, syracuse, NY, 8Northwestern University, Chicago, IL, 9Stanford University, Los Angeles, CA, 10Georgetown University, Pasadena, CA, 11Feinstein Institutes for Medical Research, New York, NY, 12SUNY Upstate University Hospital, Department of Pathology, Syracuse, NY, 13University of Rochester, Rochester, NY, 14Cedars Sinai, Los Angeles, CA

    Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease of unknown etiology with significant mortality attributed to infections due to toxicity of immunosuppressant medications. Our…
  • Abstract Number: 2634 • ACR Convergence 2024

    Transcriptomic Stratification Predicts Response to Rituximab, Abatacept or the Association of Hydroxychloroquine and Leflunomide in 3 Randomized Controlled Clinical Trials in Sjögren’s Disease

    Baptiste Chevet1, Valerie Devauchelle2, Elena Pontarini3, Valentin Baloche4, Michele Bombardieri5, Simon Bowman6, Michael Barnes7, Antoine Sreih8, Jinqi Liu8, Sheila Kelly9, Antonia Christodoulou8, Hussain Badani10, Philippe Moigeon11, Laurence LAIGLE12, Perrine Soret13, Christelle Le dantec14, Jacques-Olivier Pers15, Marta Alarcon-Riquelme16, Guillermo Barturen17, Xavier Mariette18, Joel Van Roon19, Raphaele Seror20, Gaetane Nocturne18, Divi Cornec21 and Nathan Foulquier14, and PRECSEADS Clinical Consortium and NECESSITY consortium, 1University Hospital of Brest, Brest, France, 2UBO, Brest, France, 3William Harvey Research Institute, London, United Kingdom, 4University Medical Center, Utrecht, Utrecht, Netherlands, 5Centre for Experimental Medicine and Rheumatology, The William Harvey Research Institute, Queen Mary University of London, London, United Kingdom, 6Department of Rheumatology, University Hospital Birmingham, Birmingham, United Kingdom, 7William Harvey Research institute, Centre for Translational Bioinformatics, London, United Kingdom, 8Bristol Myers Squibb, Princeton, NJ, 9Bristol Myers Squibb, Doylestown, PA, 10Bristol Myers Squibb, Lawrence Township, NJ, 11Servier Laboratories, France, Gif sur Yvette, France, 12Servier Laboratories, France, SURESNES, France, 13Servier, Paris-Saclay, Paris, Ile-de-France, France, 14LBAI. UMR 1227, University of Brest, Brest, France, 15University of Brest, Brest, France, 16Fundación Progreso y Salud, Andalusian Government, Granada, Spain, 17Center for Genomics and Oncological Research (GENYO), Andalusia, Spain, 18Service de Rhumatologie, Hôpital Bicêtre, AP-HP, Le Kremlin Bicetre, France, 19University Medical Center Utrecht, Utrecht, Netherlands, 20Service de Rhumatologie, Hôpital Bicêtre, AP-HP, le Kremlin Bicetre, Ile-de-France, France, 21Service de Rhumatologie, CHU de Brest, Brest, France

    Background/Purpose: Sjögren’s disease (SjD) is a clinically and biologically heterogeneous disease. To date, no phase-III trial showed efficacy in reducing the symptoms or systemic activity…
  • Abstract Number: 2654 • ACR Convergence 2024

    Adapting and Testing a Cognitive Rehabilitation Intervention Tailored for People with Systemic Sclerosis: Acceptability, Feasibility, & Impact on Health-related Outcomes

    Yen Chen1, Mary Alore2, Dinesh Khanna1 and Susan Murphy3, 1University of Michigan, Ann Arbor, MI, 2Self-employed, TROY, MI, 3University of Michigan, Plymouth, MI

    Background/Purpose: Cognitive dysfunction affects up to 87% of individuals with systemic sclerosis (SSc), often significantly impairing their work and daily activities and exacerbating other symptoms…
  • Abstract Number: 2664 • ACR Convergence 2024

    BCMA-targeted Bispecific T Cell-engager Therapy of Autoimmune Disease

    Laura Bucci1, Melanie Hagen2, Sebastian Boeltz2, Danae-Mona Noethling2, Tobias Rothe2, Maria Gabriella Raimondo1, Carlo Tur1, Andreas Wirsching1, Jochen Wacker1, Aline Bozec1, Georg Schett3 and Ricardo Grieshaber-Bouyer2, 1Department of Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Bayern, Germany, 2Department of Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Germany, 3Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany

    Background/Purpose: Targeting B cells and plasma cells is a key therapeutic strategy in autoimmune disease(AID). Therapy with CD19-targeted chimeric antigen receptor (CAR) T-cells and bi-specific…
  • Abstract Number: 2657 • ACR Convergence 2024

    Prevalence of Anxiety, Depression, and Fatigue in Patients with Rheumatic Diseases: A Cross-Sectional Study of 1014 Cases

    Gabriela Anais Madrid-Lopez1, Maria Corral-Trujillo2, Amado Arturo Diaz-Guerrero3, Luisa Fernanda Mata-Torres3, Eva Galindo Calvillo4, Jesus Cardenas-de la Garza2, Ivan Hernandez Galarza5, Miguel Angel Villarreal-Alarcon6 and Dionicio Galarza-Delgado7, 1Facultad de Medicina, Universidad Autónoma de Nuevo León, Monterrey, Nuevo León, Mexico, 2Universidad Autónoma de Nuevo León, Monterrey, Nuevo León, Mexico, 3Universidad Autónoma de Nuevo León, Monterrey, Mexico, 4Universidad Autónoma de Nuevo León, Saltillo, Coahuila, Mexico, 5University Hospital, UANL, San Pedro Garza Garcia, Nuevo León, Mexico, 6Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Mexico, 7UANL Hospital Universitario, Monterrey, Nuevo León, Mexico

    Background/Purpose: Individuals diagnosed with rheumatic diseases (RD) have an elevated susceptibility to mental health disorders. A study conducted among patients with RD revealed a prevalence…
  • Abstract Number: PP01 • ACR Convergence 2024

    An OCEAN of Change: The Impact of an RA Diagnosis on My Big Five Personality Traits

    Laura Sambursky1 and Lauren Sambursky2, 1Patient, Sarasota, FL, 2Northeastern University, Boston, MA

    Background/Purpose: Until age 32, I was a healthy, confident, extraverted, and creative person. I moved hundreds of miles away for college and then earned a…
  • « Previous Page
  • 1
  • …
  • 191
  • 192
  • 193
  • 194
  • 195
  • …
  • 2607
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology